High Prevalence of Pulmonary Arterial Hypertension and R&D of New Formulations of Treprostinil to Augment Growth of Treprostinil Drugs Market
Treprostinil is an antihypertensive agent used to treat patients with pulmonary arterial hypertension. It can also be used in the treatment of Degos disease, an extremely rare disorder in which small and medium-sized arteries become blocked (occlusive arteriopathy), restricting the flow of blood to affected areas. Market Dynamics The high prevalence of pulmonary arterial hypertension is expected to propel the growth of the treprostinil drugs market. For instance, according to the study, ‘High Geographic Prevalence of Pulmonary Artery Hypertension: Associations with Ethnicity, Drug Use, and Altitude’, published in February 2020, in the journal Pulmonary Circulation, the overall pulmonary arterial hypertension incidence was 14 cases per million and the annual period prevalence of pulmonary arterial hypertension was 93 cases per million. R&D of new formulations of treprostinil is expected to offer lucrative growth opportunities for players in the treprostinil drugs ma...